Utidelone recommended by “2023 CSCO Guidelines for Diagnosis and Treatment of Breast Cancer” as Class I
2023
查看大圖
2022
UTD1 Phase 3 INDs approved by NMPA for NSCLC and BC neoadjuvant; UTD2 Phase 1 INDs approved by FDA and NMPA
查看大圖
2023
Utidelone listed in “China's national reimbursement drug list”
查看大圖
2022
Biostar Pharma, Inc. (US subsidiary) incorporated
查看大圖
2021
Extraordinary general meeting held and share-holding reform completed
查看大圖
2021
Utidelone Injectable NDA approval for the first indication of advanced breast cancer
查看大圖
2020
Pre-IPO financing of 890 million RMB
查看大圖
2018
Utidelone Injectable NDA submission as priority review
查看大圖
2017
Chengdu manufacturing base established for microbial fermentation production and drug product manufacturing
查看大圖
2016
Utidelone Injectable Phase 3 reached the primary endpoint
查看大圖
2015
Wholly-owned subsidiary incorporated in Chengdu
查看大圖
2012
R&D center established covering key biosynthesis platforms
查看大圖
2011
Utidelone Injectable Phase 2/3 IND approved
查看大圖
2007
Utidelone injectable Phase 1 IND approved
查看大圖
2002
Beijing Biostar Pharmaceuticals incorporated in Beijing China
查看大圖